Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 18/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | NPC1 | O15118 | 3/20 | 0.88 |
| ▸ | RAB9A | P51151 | 3/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31243 | 0.94 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4912951 | 0.91 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4920310 | 0.90 | SCD (0.88) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4919654 | 0.90 | SCD (0.88) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2753553 | 0.90 | SCD (0.93) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4913650 | 0.90 | SCD (0.88) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16681363 | 0.90 | SCD (0.88) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4917823 | 0.90 | SCD (0.87) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16554160 | 0.90 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4918742 | 0.89 | SCD (0.86) | SCDKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3041470-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | Board Of Regents Of the University Of Texas System (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | SCD 4/4885KMT2A 1976/4885MEN1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.